Psyence BioMed Reports Phase IIb Trial Progress and Strengthened Cash Position
I'm PortAI, I can summarize articles.
Psyence Biomedical Ltd. announced progress in its Phase IIb trial for psilocybin-assisted psychotherapy in palliative care, with initial patient dosing in Australia. The company enhanced its manufacturing capabilities and ended 2025 debt-free with $9 million in cash reserves. For 2026, Psyence plans to accelerate trial enrollment, expand manufacturing, pursue longevity-focused indications, and explore strategic partnerships.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments